We’re Developing The Next Generation Of Parkinson’s Therapies, And Here's How - Brenig Therapeutics

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.This week on Leading Beyond The Lab, Lawrence Rose sat down with Megan McGill, CEO of Brenig Therapeutics, with years of experience spanning biotech leadership, strategy, clinical medicine, management consulting and neuroscience research.In this episode, Megan covers:• Why Brenig Therapeutics is targeting neuroinflammation and Parkinson’s disease through LRRK2 and NLRP3 inhibitors, and how the company is positioning itself within the rapidly evolving neurodegenerative disease landscape.• How AI and machine learning are being used across medicinal chemistry and drug development at Brenig through investment from Torrey Pines, OrbiMed, New Enterprise Associates, BioGeneration Ventures, to optimise brain penetration, selectivity and safety profiles simultaneously.• Why Megan believes an MD and PhD background is critical in biotech leadership, combining a deep understanding of disease biology with a real-world understanding of patients and unmet medical needs.• The realities of building a career in medicine, biotech and leadership while raising children as a single mother, and the leadership lessons around empathy, patience and resilience that came from that experience.• Why neuroscience investment remains significantly underfunded despite the growing global burden of neurodegenerative disease, and what needs to change across biotech, pharma and venture capital to accelerate progress in CNS innovation.• Lawrence and Megan also discuss organisations and companies including Eli Lilly and Company, McKinsey & Company, BridgeBio Pharma and the Michael J. Fox Foundation.Be sure to check out the full episode to hear Megan’s perspective on the future of neuroscience, biotech leadership and the evolving role of AI across drug development.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentMegan McGillCEO at Brenig TherapeuticsLinkedIn: https://www.linkedin.com/in/mcgillmegan/Lawrence RoseConsulting Director at ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Introduction02:21 Megan’s background across medicine, biotech and neuroscience03:03 Joining Brenig Therapeutics and the company’s pipeline04:16 LRRK2 and NLRP3 inhibitors in Parkinson’s disease05:23 The growing neuroinflammation landscape06:51 Phase 1 clinical trial milestones and biomarkers07:23 Why Brenig chose Parkinson’s disease10:14 AI medicinal chemistry and machine learning in drug discovery12:08 How AI is changing biotech operations and strategy14:20 Brenig’s Series B strategy and upcoming milestones15:57 Building efficient biotech teams and scaling operations17:30 Leadership inspiration and high-performing teams18:46 The advantages of being an MD and PhD in biotech leadership21:16 Commercial partnerships and pharma collaboration strategy23:08 Digital biomarkers, diagnostics and wearable technology28:06 Balancing medicine, biotech leadership and motherhood33:30 Mentorship, McKinsey and learning commercial strategy37:00 Leadership communication and simplifying complexity38:23 What defines elite biotech teams and company culture40:40 Brenig’s board, investors and strategic support43:16 Building a culture of excellence in a virtual biotech company46:13 The future of neuroscience and neurodegenerative disease50:25 Clinical trial recruitment and patient engagement52:34 The Biotech CEO Sisterhood and women in biotech leadership56:17 Diversity, leadership and representation in biotech Hosted on Acast. See acast.com/privacy for more information.